Center for Radiopharmaceutical Sciences, Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland.
Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland.
J Med Chem. 2022 Feb 10;65(3):2191-2207. doi: 10.1021/acs.jmedchem.1c01706. Epub 2022 Jan 28.
Monoacylglycerol lipase (MAGL) is one of the key enzymes in the endocannabinoid system. Inhibition of MAGL has been proposed as an attractive approach for the treatment of various diseases. In this study, we designed and successfully synthesized two series of piperazinyl pyrrolidin-2-one derivatives as novel reversible MAGL inhibitors. ()-[F] was identified through the preliminary evaluation of two carbon-11-labeled racemic structures [C] and [C]. In dynamic positron-emission tomography (PET) scans, ()-[F] showed a heterogeneous distribution and matched the MAGL expression pattern in the mouse brain. High brain uptake and brain-to-blood ratio were achieved by ()-[F] in comparison with previously reported reversible MAGL PET radiotracers. Target occupancy studies with a therapeutic MAGL inhibitor revealed a dose-dependent reduction of ()-[F] accumulation in the mouse brain. These findings indicate that ()-[F] ([F]YH149) is a highly promising PET probe for visualizing MAGL non-invasively and holds great potential to support drug development.
单酰基甘油脂肪酶(MAGL)是内源性大麻素系统的关键酶之一。抑制 MAGL 已被提议作为治疗各种疾病的一种有吸引力的方法。在这项研究中,我们设计并成功合成了两个系列的哌嗪基吡咯烷-2-酮衍生物,作为新型的可逆 MAGL 抑制剂。通过初步评估两种碳-11 标记的外消旋结构 [C] 和 [C],确定了 ()-[F]。在动态正电子发射断层扫描(PET)扫描中,()-[F]显示出不均匀的分布,与小鼠大脑中的 MAGL 表达模式相匹配。与之前报道的可逆 MAGL PET 放射性示踪剂相比,()-[F]在脑内的摄取量和脑血比均较高。用一种治疗性 MAGL 抑制剂进行的靶部位占有率研究表明,()-[F]在小鼠脑内的积累呈剂量依赖性减少。这些发现表明,()-[F]([F]YH149)是一种很有前途的用于非侵入性可视化 MAGL 的 PET 探针,并且具有很大的潜力来支持药物开发。